Device Trial Radar · NCT00830440
A Multicenter Study for Pre-Surgical Weight Loss
Last checked: Nov 20, 2026Latest source record: May 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
43
Actual
Start
Jan 2007
Primary completion
Mar 2008
Study completion Sep 2008
Sponsor
- Lead sponsor
- Morphic Medical Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jan 28, 2009
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the safety and initial efficacy of the EndoBarrier device compared to a diet control in patients who require weight loss prior to their Bariatric surgery. It is a randomized, prospective controlled, open label, pilot study of 40 patients. Thiry patients will receive an implant of the EndoBarrier device and the other 10 patients will receive the principle investigator's standard of care diet program. All patients will be treated for 12 weeks with the exception of the last 10 device patients who will continue to 24 weeks if the principle investigator determines that it is safe and in their best interest to continue. The primary efficacy endpoint is: * Assessment of the difference in % excess weight loss between the 2 groups Secondary endpoints are: * Resolution or Improvement in type II Diabetic status as defined as: * Resolution = patient is off their diabetes medication and has normal diabetic blood parameters (fasting glucose) * Improvement = normalizing diabetic blood parameters (fasting glucose) and/or a reduction in dosing or frequency of their diabetic medication * The percent of patients who achieve at least a 10% excess weight loss will be calculated as a secondary outcome.
Conditions
- Obesity
Interventions
EndoBarrier DeviceDevice
NIH derived dietary, exercise and behavior modification 2005 guidelines. https://health.gov/dietaryguidelines/2005.asp and EndoBarrier Device for 12 weeks
Diet & Lifestyle CounselingBehavioral
NIH derived dietary, exercise and behavior modification 2005 guidelines. https://health.gov/dietaryguidelines/2005.asp
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total Weight Change From Baseline at 12 Weeks in kgTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital Maastricht
Maastricht, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.